The estimated Net Worth of Alfred D Kingsley is at least 5.85 百万$ dollars as of 14 June 2023. Mr. Kingsley owns over 30,000 units of Lineage Cell Therapeutics Inc stock worth over 405,875$ and over the last 21 years he sold LCTX stock worth over 5,442,001$. In addition, he makes 0$ as Chairman of the Board at Lineage Cell Therapeutics Inc.
Sign up
Mr. Kingsley LCTX stock SEC Form 4 insiders trading
Alfred has made over 16 trades of the Lineage Cell Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of LCTX stock worth 6,300$ on 14 June 2023.
The largest trade he's ever made was selling 344,828 units of Lineage Cell Therapeutics Inc stock on 15 November 2012 worth over 1,000,001$. On average, Alfred trades about 47,074 units every 79 days since 2003. As of 14 June 2023 he still owns at least 469,111 units of Lineage Cell Therapeutics Inc stock.
You can see the complete history of Mr. Kingsley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alfred Kingsley biography
Alfred D. Kingsley J.D. serves as Chairman of the Board of the Company. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt served as our financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation (OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer. From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also served as a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until our acquisition of Asterias in March 2019. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York University Law School. Mr. Kingsley’s long career in corporate finance and mergers and acquisitions includes substantial experience in helping companies to improve their management and corporate governance, and to restructure their operations. Mr. Kingsley developed an intimate knowledge of our business in his role as our financial advisor before he joined our Board. Mr. Kingsley has been instrumental in structuring our equity and debt financings, and in the transition of our business focus into the field of stem cell technology, and the business acquisitions that have helped us expand the scope of our business.
How old is Alfred Kingsley?
Alfred Kingsley is 77, he's been the Chairman of the Board of Lineage Cell Therapeutics Inc since 2009. There are no older and 16 younger executives at Lineage Cell Therapeutics Inc.
What's Alfred Kingsley's mailing address?
Alfred's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.
Insiders trading at Lineage Cell Therapeutics Inc
Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over 2,612,743$ worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth 8,569,904$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Alfred D Kingsley、Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of 212,992$. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth 9,345$.
What does Lineage Cell Therapeutics Inc do?
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
What does Lineage Cell Therapeutics Inc's logo look like?
Complete history of Mr. Kingsley stock trades at Oncocyte、Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc executives and stock owners
Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brandi Roberts,
Chief Financial Officer -
Brian M. Culley M.A., M.B.A.,
CEO, Pres & Director -
Brian Culley,
Chief Executive Officer, Director -
Chase Leavitt,
General Counsel and Corporate Secretary -
Brandi L. Roberts,
Consultant -
Angus Russell,
Independent Director -
Michael Mulroy,
Independent Director -
Stephen Farrell,
Independent Director -
Neal Bradsher,
Independent Director -
Don Bailey,
Independent Director -
Deborah Andrews,
Independent Director -
Gary Hogge,
Senior Vice President of Clinical & Medical Affairs -
Alfred Kingsley,
Chairman of the Board -
Alexandra Hernandez,
Sr. Director of Fin. & Controller -
Dr. Rami Skaliter,
Chief Exec. Officer of Cell Cure Neurosciences Ltd. -
William Annett,
Pres & CEO of OncoCyte Corp. -
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
Sr. VP of Clinical & Medical Affairs -
Dr. François Binette M.Sc., Ph.D.,
Sr. VP & Global Head of R&D -
George A. Samuel III, J.D.,
Gen. Counsel & Company Sec. -
Ioana C. Hone,
Director of Investor Relations -
Kevin L. Cook,
Chief Financial Officer -
George A. Iii Samuel,
General Counsel/Secretary -
Anula Jayasuriya,
-
Dipti Amin,
-
Neal C Bradsher,
Director -
Alexandra Hernandez,
Sr Director Finance/Controller -
Kevin Leon Cook,
Chief Financial Officer -
Jill Ann Howe,
Chief Financial Officer